

## Corporate Medical Policy

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

**File Name:** biomarker\_testing\_for\_multiple\_sclerosis\_and\_related\_neurologic\_diseases

**Origination:** 1/1/2019

**Last Review:** 11/2022

### Description of Procedure or Service

---

#### I. Policy Description

Multiple sclerosis (MS) is the most common immune-mediated inflammatory demyelinating disease of the central nervous system (CNS) and is defined by multifocal areas of demyelination with loss of oligodendrocytes and astroglial scarring. The most commonly present symptom is sensory disturbances, followed by weakness and visual disturbances. However, the disease has a highly variable pace and many atypical forms (Olek, 2022a). Besides MS, acute CNS demyelination also occurs in acute disseminated encephalomyelitis (ADEM), optic neuritis, transverse myelitis, and neuromyelitis optica (Lotze, 2022).

Neuromyelitis optica and neuromyelitis optica spectrum disorders (NMOSD) are inflammatory disorders of the CNS characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting optic nerves and spinal cord. Previously considered a subset of MS, this set of disorders is now recognized as its own clinical entity with its own unique immunologic features (Glisson, 2022).

#### II. Scientific Background

In the United States, the 2010 estimated prevalence of multiple sclerosis (MS) is 309.2 per 100,000 individuals, totaling 727,344 persons with MS (Wallin et al., 2019). The mean age of MS onset ranges from 28 to 31 years of age with clinical disease usually becoming apparent between the ages of 15 to 45 years, though in rare instances, onset has been noted as early as the first years of life or as late as the seventh decade (Goodin, 2014). Prevalence of MS is highest in the 55- to 65- year age group (Wallin et al., 2019). In most, but not all, cases, a patient presents with a clinically isolated syndrome (CIS) as the first single clinical event. This CIS precludes a clinically definite MS (Lublin et al., 2014). The pattern and course of MS is then further categorized into several clinical subtypes (Lublin & Reingold, 1996; Lublin et al., 2014): Relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). RRMS is the most common type of disease course (85 to 90 percent of cases at onset (Weinshenker, 1994) and is characterized by clearly defined relapses with full recovery, or with sequelae and residual deficit upon recovery. The transition from RRMS to SPMS usually occurs 10 to 20 years after disease onset (Eriksson et al., 2003). SPMS is characterized by an initial RRMS disease course followed by gradual worsening with or without occasional relapses, minor remissions, and plateaus. Primary progressive multiple sclerosis (PPMS) is characterized by progressive accumulation of disability from disease onset with occasional plateaus, temporary minor improvements, or acute relapses still consistent with the definition. A diagnosis of PPMS is made exclusively on patient history, and there are no imaging or exam findings that distinguish PPMS from RRMS. PPMS represents about 10 percent of MS cases at disease onset (Koch et al., 2009; Olek, 2022a). Worsening of disability

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

due to MS is highly variable. The impact of MS varies according to several measures, including severity of signs and symptoms, frequency of relapses, rate of worsening, and residual disability. Worsening of disability over time is a critical issue for MS patients (Olek, 2022a). Current treatments can delay the progression of the disease. However, this delay is only achievable if treatment starts at the beginning of the disease. Thus, it is essential that a proper diagnosis is made as early as possible, allowing for early treatment and as much delay as possible in symptom progression (Sapko et al., 2020).

Multiple sclerosis is primarily diagnosed clinically. The core requirement for the diagnosis is the demonstration of central nervous system lesion dissemination in time and space, based upon either clinical findings alone or a combination of clinical and MRI findings. The history and physical examination are most important for diagnostic purposes. MRI is the test of choice to support the clinical diagnosis of MS (Filippi & Rocca, 2011). The McDonald diagnostic criteria include specific MRI criteria for the demonstration of lesions dissemination in time and space; however, the McDonald criteria are not intended for distinguishing MS from other neurologic conditions (Brownlee et al., 2017). The sensitivity and specificity of MRI for the diagnosis of MS varies widely in different studies. This variation is probably due to differences among the studies in MRI criteria and patient populations (Offenbacher et al., 1993; Schaffler et al., 2011). Using the 2010 McDonald criteria, the sensitivity and specificity were approximately 53 and 87 percent, respectively (Rovira et al., 2009). In the first studies applying the 2017 criteria (Hyun et al., 2018), the sensitivity is higher (83.6%), but the specificity is lower (85%).

Qualitative assessment of cerebrospinal fluid (CSF) for oligoclonal IgG bands (OCBs) using isoelectric focusing can be an important diagnostic tool when determining a diagnosis of MS. Elevation of the CSF immunoglobulin level relative to other protein components is a common finding in patients with MS and suggests intrathecal synthesis. The immunoglobulin increase is predominantly IgG, although the synthesis of IgM and IgA is also increased (Olek, 2022a). A positive finding is defined by “finding of either oligoclonal bands different from any such bands in serum, or by an increased IgG index” and can be measured by features such as percentage of total protein or total albumin. Up to 95% of clinically definite MS cases will have these oligoclonal bands (Olek, 2022).

The 2017 McDonald criteria allows for the presence of CSF oligoclonal bands to substitute for the diagnostic requirement of fulfilling dissemination in time. However, Thompson notes that “currently, no laboratory test in isolation confirms the diagnosis of multiple sclerosis” (Thompson et al., 2018). Luzzio (2019) et al also note that in a review of four guidelines from the Consortium of Multiple Sclerosis Centers, the European Academy of Neurology, and the Magnetic Resonance Imaging in MS Network, MRI is the “imaging procedure of choice for confirming MS and monitoring disease progression in the brain and spinal cord” (Luzzio, 2019).

Neuromyelitis optica spectrum disorders (NMOSD, also known as Devic disease or neuromyelitis optica, NMO) are a range of conditions that are characterized by symptoms similar to MS; namely demyelination and axonal damage to structures of the central nervous system, such as the spinal cord. Previously, NMOSD were considered a subset of MS; however, now NMOSD and NMO are recognized as having distinct features, specifically the presence of NMOSD/NMO-specific antibody that binds aquaporin-4 (AQP4), setting these apart from relapsing-remitting MS. AQP4 is a water channel protein primarily located in the spinal cord gray matter. NMO-IgG (or anti-AQP4) is involved in the pathogenesis of NMOSD/NMO. This antibody selectively binds AQP4, differing from MS in that the loss of AQP4 expression is unrelated to the stage of demyelination. The presence of this antibody is incorporated into the current diagnostic criteria for NMOSD and can differentiate MS cases from NMOSD cases (Glisson, 2022).

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

## *Clinical Utility and Validity*

There is a strong unmet clinical need for objective body fluid biomarkers to assist early diagnosis and estimate long-term prognosis, monitor treatment response, and predict potential adverse effects in MS. Currently, no biomarkers of MS have been validated; however, many are under consideration: microRNA (miRNA), messenger RNA (mRNA), lipids, autoantibodies, metabolites and proteins all have been reported to have potential as possible biomarkers (Comabella & Montalban, 2014; Comabella et al., 2016; El Ayoubi & Khoury, 2017; Lim et al., 2017; Raphael et al., 2015; Teunissen et al., 2015).

Fryer et al. (2014) compared three assays for measuring aquaporin-4 IgG: ELISA, fixed cell-based fluorescence (CBA), and live cell-based fluorescence (FACS, M1 and M23 versions). Four groups of patients were measured with these assays. In Group 1 (n = 388), FACS was optimal, with the highest area under the curve. In Group 2, FACS identified the highest percentage of neuromyelitis optica spectrum disorders, identifying 23 (M1) and 24 (M23) of 30 patients. In Group 3, all four assays identified true negatives at an approximate 85% success rate (5 of 31 positives). In Group 4, all four assays identified true positives in 40 of 41 samples. The authors noted that “aquaporin-4-transfected CBAs, particularly M1-FACS, perform optimally in aiding NMOSD serologic diagnosis” (Fryer et al., 2014).

Jitrapaikulsan et al. (2018) evaluated the prognostic value of aquaporin-4 IgG and myelin oligodendrocyte glycoprotein IgG (MOG) in patients with recurrent optic neuritis (rON). The study included 246 and autoantibodies were detected in 32% of these patients (aquaporin-4 in 19%, MOG in 13%). 186 patients had rON only and 60 patients had “additional inflammatory demyelinating attacks” (rON plus). Of the 186 rON only patients, 27 were positive for MOG, 24 were positive for aquaporin-4, and 110 were negative for both. In the rON plus group, 23 were positive for aquaporin-4, 4 were positive for MOG, and 11 were negative for both. The authors noted that 5 years after optic neuritis onset, 59% of aquaporin-4 positive patients and 12% of MOG positive patients were estimated to have “severe visual loss”. The authors concluded that “aquaporin-4 IgG seropositivity predicts a worse visual outcome than MOG IgG1 seropositivity, double seronegativity, or MS diagnosis. Myelin oligodendrocyte glycoprotein IgG1 is associated with a greater relapse rate but better visual outcomes” (Jitrapaikulsan et al., 2018).

Sotirchos et al. (2019) compared 31 healthy controls with individuals with one of three types of optic neuritis (ON): 48 individuals with aquaporin-4 IgG-associated ON (AQP4-ON), 16 individuals with myelin oligodendrocyte glycoprotein-IgG-associated ON (MOG-ON), and 40 individuals with MS-associated ON (MS-ON). The authors note, “AQP4-ON eyes exhibited worse high-contrast letter acuity (HCLA) compared to MOG-ON ( $-22.3 \pm 3.9$  letters;  $p < 0.001$ ) and MS-ON eyes ( $-21.7 \pm 4.0$  letters;  $p < 0.001$ ). Macular ganglion cell + inner plexiform layer (GCIPL) thickness was lower, as compared to MS-ON, in AQP4-ON ( $-9.1 \pm 2.0$   $\mu\text{m}$ ;  $p < 0.001$ ) and MOG-ON ( $-7.6 \pm 2.2$   $\mu\text{m}$ ;  $p = 0.001$ ) eyes. Lower GCIPL thickness was associated with worse HCLA in AQP4-ON ( $-16.5 \pm 1.5$  letters per 10  $\mu\text{m}$  decrease;  $p < 0.001$ ) and MS-ON eyes ( $-8.5 \pm 2.3$  letters per 10  $\mu\text{m}$  decrease;  $p < 0.001$ ), but not in MOG-ON eyes ( $-5.2 \pm 3.8$  letters per 10  $\mu\text{m}$  decrease;  $p = 0.17$ ), and these relationships differed between the AQP4-ON and other ON groups ( $p < 0.01$  for interaction).” These data indicate that AQP4-IgG seropositivity suggests worse visual outcomes than those occurring after MOG-ON or even MS-ON (Sotirchos et al., 2019).

Cantó et al. (2019) evaluated neurofilament light chain’s (NfL) ability to “serve as a reliable biomarker of disease worsening for patients with multiple sclerosis (MS).” The study included 607 patients with MS; patients were assessed over a period of 12 years. Serum NfL was measured, and disability progression was the primary clinical outcome (defined as “clinically significant worsening on the Expanded Disability Status Scale (EDSS) score and brain fraction

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

atrophy”). Baseline measurements of NfL showed significant association with EDSS score, MS subtype, and treatment status. Worsening EDSS score and changes of NfL levels over time were found to be correlated. The baseline NfL measurement was also found to be associated with approximately 11.6% of brain fraction atrophy over 10 years; increasing to 18% after multivariable analysis. Furthermore, active treatment was associated with declining levels of NfL, with “high-potency treatments” associated with the greatest decrease out of all the treatments assessed. Overall, the authors concluded that they had confirmed a significant association of serum NfL with clinical outcomes of MS. However, they also acknowledged that “further prospective studies are necessary to assess the assay’s utility for decision-making in individual patients” (Cantó et al., 2019).

Gil-Perotin et al. (2019) evaluated the combined biomarker profile of NfL and chitinase3-like1 (CHI3L1) and its ability to provide prognostic information for patients with MS. 157 MS patients were included, with 99 RRMS patients, 35 SPMS patients, and 23 PPMS patients. Disease activity was defined by “clinical relapse and/or gadolinium-enhanced lesions (GEL) in MRI within 90 days from CSF collection”. Levels of both biomarkers were found to be higher in MS patients compared to non-MS patients. Elevated NfL was associated with clinical relapse and GEL in RRMS and SPMS patients and high CHI3L1 levels were characteristic of progressive disease. The authors also found the combined profile useful for differentiating between MS subtypes, with high NfL and low CHI3L1 often indicating a RRMS stage. They found that elevation of both biomarkers indicates disease progression. Overall, the authors concluded these biomarkers were useful for disease activity and progression, and that the biomarker profile can discriminate between MS subtypes (Gil-Perotin et al., 2019).

Martin et al. (2019) performed a meta-analysis to evaluate the CSF levels of NfL to determine “whether, and to what degree, CSF NfL levels differentiate MS from controls, or the subtypes or stages of MS from each other”. The authors identified 14 articles for inclusion in their meta-analysis. NfL levels were higher in MS patients (746) than controls (435) (mean of 1965.8 ng/L in MS patients compared to 578.3 ng/L in healthy controls). Mean NfL levels were found to be higher in 176 patients with relapsing disease (mean = 2124.8ng/L) compared to 92 patients with progressive disease (mean = 1121.4ng/L). The authors also found that patients with relapsing disease (138 in this cohort) had approximately double the levels of CSF NfL compared to patients in remission (268), with an average of 3080.6ng/L in the relapsing cohort compared to 1541.7ng/L in the remission cohort. Overall, the authors concluded that CSF NfL correlates with MS activity throughout the course of disease, that relapse was more strongly associated with elevated CSF NfL levels, and that CSF NfL may be useful as a measure of activity (Martin et al., 2019).

Simonsen et al. (2020) performed a retrospective study investigating if analysis of IgG index could safely predict oligoclonal band (OCB) findings. 1295 MS patients were included, with 93.8% of them positive for OCBs. Of 842 MS patients with known IgG status and known OCB status, 93.3% were oligoclonal band positive and 76.7% were found to have an elevated IgG profile. The authors found the positive predictive value of elevated IgG based on positive OCBs to be 99.4%, and the negative predictive value of normal IgG based on negative OCBs to be 26.5%. The authors concluded that an IgG index of >0.7 has a positive predictive value of >99% for OCBs (Simonsen et al., 2020).

Benkert et al. (2022) conducted a retrospective modelling and validation study aiming to assess the ability of serum neurofilament light chain (sNfL) to identify people at risk of future MS. The authors used a reference database to determine reference values of sNfL corrected for age and body mass index (BMI). The study included a control group (no history of CNS disease) and MS patients. In the control group, sNfL concentrations increased exponentially with age; the rate of increase rose after the age of 50. In MS patients, “sNfL percentiles and Z scores indicated a gradually increased risk for future acute (eg, relapse and lesion formation) and chronic (disability worsening) disease activity.” The authors collected data before and

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

after MS treatment and found that sNfL Z score values decreased to the level of the control group with monoclonal antibodies, and, to a lesser extent, with oral therapies. sNfL Z scores did not decrease with platform compounds such as interferons and glatiramer acetate. The authors conclude that “use of sNfL percentiles and Z scores allows for identification of individual people with multiple sclerosis at risk for a detrimental disease course and suboptimal therapy response beyond clinical and MRI measures, specifically in people with disease activity-free status” (Benkert et al., 2022).

## III. State and Federal Regulations, as applicable

### Food and Drug Administration (FDA)

In 2016, the FDA approved the KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay. The indication for use is as follows: “The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is for the semi-quantitative determination of autoantibodies to Aquaporin-4 in human serum. The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay may be useful as an aid in the diagnosis of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay is not to be used alone and is to be used in conjunction with other clinical, laboratory, and radiological (e.g. MRI) findings” (FDA, 2016).

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

**\*\*\*Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.**

## Policy

---

**BCBSNC will provide coverage for biomarker testing for multiple sclerosis and related neurologic diseases when it is determined the medical criteria or reimbursement guidelines below are met.**

## Benefits Application

---

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

## When biomarker testing for multiple sclerosis and related neurologic diseases is covered

---

1. Reimbursement for cerebrospinal fluid (CSF) and serum oligoclonal band analysis for the diagnosis of multiple sclerosis is allowed in any of the following situations
  - a. For individuals with atypical clinical, laboratory, or imaging features
  - b. For individuals with an atypical, clinically isolated syndrome, including, but not limited to, primary progressive multiple sclerosis or relapsing-remitting course
  - c. For individuals belonging to a population in which MS is less common, including, but not limited to children, older individuals, or non-Caucasians

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

2. Reimbursement for serum indirect fluorescence assay or fluorescence-activated cell sorting (FACS) assay of aquaporin-4-IgG (AQP4-IgG) and MOG-IgG in cases of suspected neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) is allowed when **all** of the following conditions are met:
  - a. The individual has monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof;
  - b. The individuals have radiological or electrophysiological findings compatible with CNS demyelination
  - c. The individual has at least one of the following:
    - i. Belongs to a higher risk population—African American, Latin American, Asian, or pediatric.
    - ii. Has an abnormal MRI depicting extensive optic nerve lesion, extensive spinal cord lesion or atrophy, or large confluent T2 brain lesions.
    - iii. Has prominent papilledema/papillitis/optic disc swelling during acute optic neuritis.
    - iv. Has neutrophilic CSF pleocytosis.
    - v. Has a histopathology finding of primary demyelination with intralesional complement and IgG deposits or has a previous diagnosis of “pattern II MS”.
    - vi. Has simultaneous bilateral acute optic neuritis.
    - vii. Has a severe visual deficit or blindness in one or both eyes during or after acute optic neuritis.
    - viii. Has severe or frequent episodes of acute myelitis or brainstem encephalitis.
    - ix. Has permanent sphincter and/or erectile disorder after myelitis.
    - x. Has a previous diagnosis of acute disseminated encephalomyelitis (ADEM).

## When biomarker testing for multiple sclerosis and related neurologic diseases is not covered

1. Reimbursement is not allowed for serum biomarker tests for multiple sclerosis in all other situations.
2. Reimbursement is not allowed for ELISA, Western blot, immunohistochemistry or any other serum assays to test for NMOSD or MOG-EM.
3. Reimbursement is not allowed for all other cerebrospinal fluid (CSF) biomarker tests, including AQP4-IgG or MOG-IgG, for the diagnosis of multiple sclerosis, NMOSD, or MOG-EM.

## Table of Terminology

Term	Definition
ADEM	Acute disseminated encephalomyelitis
AQP4Ab	Aquaporin-4 autoantibody
AQP4-IgG	Aquaporin-4-immunoglobulin G
AQP4-ON	Aquaporin-4 immunoglobulin G-Associated ON

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

BMI	Body mass index
CBA	Cell-Based immunofluorescence assay
CHI3L1	Chitinase3-like1
CIS	Clinically isolated syndrome
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid
CNS	Central nervous system
CPT	Current procedural terminology
CSF	Cerebrospinal fluid
EDSS	Expanded disability status scale
ELISA	Enzyme-linked immunosorbent immunoassay
FACS	Fluorescence-activated cell sorting
FDA	Food And Drug Administration
GCIPL	Ganglion cell + inner plexiform layer
GEL	Gadolinium-enhanced lesions
HCLA	High-contrast letter acuity
IPND	International Panel on MOG Encephalomyelitis
IVIG	Intravenous immunoglobulin treatment
LDTs	Laboratory-developed tests
miRNA	Micro ribonucleic acid
MOG	Myelin oligodendrocyte glycoprotein immunoglobulin G
MOG-EM	Myelin oligodendrocyte glycoprotein-immunoglobulin G -associated encephalomyelitis
MOG-IgG	Myelin oligodendrocyte glycoprotein- immunoglobulin G
MOG-ON	Myelin oligodendrocyte glycoprotein- immunoglobulin G -associated ON
MRI	Magnetic resonance imaging
mRNA	Messenger ribonucleic acid
MS	Multiple sclerosis
MS-ON	Multiple sclerosis-associated ON
NfL	Neurofilament light
NICE	<a href="https://www.nice.org.uk/">National Institute for Health and Care Excellence</a>
NMO	Neuromyelitis optica
NMOSD	Neuromyelitis optica spectrum disorders
OCBs	Oligoclonal immunoglobulin G Bands
ON	Optic neuritis
PPMS	Primary progressive multiple sclerosis
rON	Recurrent optic neuritis
RRMS	Relapsing-remitting multiple sclerosis
sNfL	Serum neurofilament light chain
SPMS	Secondary progressive multiple sclerosis

## Policy Guidelines

### A. Guidelines and Recommendations

#### International Advisory Committee on Clinical Trials in Multiple Sclerosis

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

In 2014, the International Advisory Committee on Clinical Trials in Multiple Sclerosis, jointly sponsored by the U.S. National Multiple Sclerosis Society, the European Committee for Treatment and Research in Multiple Sclerosis and the MS Phenotype Group, re-examined MS phenotypes, exploring clinical, imaging, and biomarker advances through working groups and literature searches. The committee concluded that “To date, there are no clear clinical, imaging, immunologic or pathologic criteria to determine the transition point when RRMS [relapse-remitting MS] converts to SPMS [secondary progressive MS]; the transition is usually gradual. This has limited our ability to study the imaging and biomarker characteristics that may distinguish this course” (Lublin et al., 2014). In 2020, the committee updated this policy for clarity, summarizing with “the committee urges clinicians, investigators, and regulators to consistently and fully use the 2013 phenotype characterizations by (1) using the full definition of activity, that is, the occurrence of a relapse or new activity on an MRI scan (a gadolinium-enhancing lesion or a new/unequivocally enlarging T2 lesion); (2) framing activity and progression in time; and (3) using the terms worsening and progressing or disease progression more precisely when describing MS course” (Lublin et al., 2020).

## **The International Panel on Diagnosis of Multiple Sclerosis**

The Panel reviewed the 2010 McDonald criteria and recommended: “In a patient with a typical clinically isolated syndrome and fulfilment of clinical or MRI criteria for dissemination in space and no better explanation for the clinical presentation, demonstration of CSF-specific oligoclonal bands in the absence of other CSF findings atypical of multiple sclerosis allows a diagnosis of this disease to be made.” The Panel goes on to state that “CSF oligoclonal bands are an independent predictor of the risk of a second attack when controlling for demographic, clinical, treatment, and MRI variables” and that in the absence of atypical CSF findings, demonstration of these CSF OCBs can allow for a diagnosis of MS to be made. The Panel remarks that inclusion of this CSF criterion can substitute for the traditional “dissemination in time” criterion, but that no laboratory test in isolation can confirm an MS diagnosis (Thompson et al., 2018).

Cerebrospinal fluid examination is “strongly recommended” in some circumstances for MS diagnosis, and the Panel remarks that the threshold for additional testing should be low. Those circumstances are as follows:

- “when clinical and brain MRI evidence supporting a diagnosis of multiple sclerosis is insufficient, particularly if initiation of long-term disease-modifying therapies are being considered”
- “when there is a presentation other than a typical clinically isolated syndrome, including patients with a progressive course at onset (primary progressive multiple sclerosis)”
- “when there are clinical, imaging, or laboratory features atypical of MS”
- “in populations in which diagnosing MS is less common (for example, children, older individuals, or non-Caucasians).”

The Panel does emphasize that it is essential for CSF to be paired with another serum sample when analyzed to demonstrate that the OCBs are unique to the CSF (Thompson et al., 2018).

The treatments for these similar conditions (MS and NMOSD) can differ, as some MS treatments (interferon beta, fingolimod, and natalizumab) can exacerbate NMOSDs. Therefore, the Panel recommended that “NMOSDs should be considered in any patient being evaluated for multiple sclerosis”. The Panel notes that aquaporin-4 serological testing “generally differentiates” NMOSD from MS (Thompson et al., 2018). Serological testing for AQP4 and for MOG should be done in all patients with features suggesting NMOSDs (severe brainstem involvement, bilateral optic neuritis, longitudinally extensive spinal cord lesions, large cerebral lesions, or a normal brain MRI or findings not fulfilling dissemination in space



# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

[DIS]), and considered in groups at higher risk of NMOSDs (African American, Asian, Latin American, and pediatric populations) (Thompson et al., 2018).

## International Panel on MOG encephalomyelitis (IPND)

Human myelin oligodendrocyte glycoprotein (MOG-IgG)-associated encephalomyelitis (MOG-EM) is considered a unique disease from MS and other NMOSD, but MOG-EM has often been misdiagnosed as MS in the past. In 2018, an international panel released their recommendations concerning diagnosis and antibody testing. They state their purpose with the following: “To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation” (Jarius et al., 2018).

They list the following recommendations:

- Assay: Indirect fluorescence assays, including fluorescence-activated cell sorting (FACS) that targets full-length human MOG (IgG-specific), are the gold standards. The use of either IgM or IgA antibodies are less specific and can result in both false-negative results due to high-affinity IgG displacing IgM and false-positive results due to cross-reactivity with rheumatoid factors.
- Immunohistochemistry is NOT recommended because it is “less sensitive than cell-based assays, limited data available on specificity, [and] sensitivity depends on tissue donor species.”
- Peptide-based ELISA and Western blot are NOT recommended because they are “insufficiently specific, obsolete.”
- Biomaterial: Serum is the recommended specimen of choice. CSF is “not usually required” because “MOG-IgG is produced mostly extrathecally, resulting in lower CSF than serum titers.”
- Timing of testing: Serum concentration of MOG-IgG is highest during an acute attack and/or while not receiving immunosuppressive treatment. MOG-IgG concentration may decrease during remission. “If MOG-IgG test is negative but MOG-EM is still suspected, re-testing during acute attacks, during treatment-free intervals, or 1-3 months after plasma exchange (or IVIG [intravenous immunoglobulin treatment]) is recommended.”
- “Given the very low pre-test probability, we recommend against general MOG-IgG testing in patients with a progressive disease course.”
- “In practice, many patients diagnosed with AQP4-IgG-negative NMOSD according to the IPND 2015 criteria will meet also the criteria for MOG-IgG testing...and should thus be tested. However, MOG-IgG testing should not be restricted to patients with AQP4-IgG-negative NMOSD” (Jarius et al., 2018).

The Table below outlines the recommendation on the criteria required for testing:

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

**Table 1** Recommended indications for MOG-IgG testing in patients presenting with acute CNS demyelination of putative autoimmune etiology

1. Monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof,  
*and*
2. radiological or, only in patients with a history of optic neuritis, electrophysiological (VEP) findings compatible with CNS demyelination,  
*and*
3. at least one of the following findings:  
*MRI*
  - a. Longitudinally extensive spinal cord lesion ( $\geq 3$  VS, contiguous) on MRI (so-called LETM)<sup>a,b</sup>
  - b. Longitudinally extensive spinal cord atrophy ( $\geq 3$  VS, contiguous) on MRI in patients with a history compatible with acute myelitis<sup>a</sup>
  - c. Conus medullaris lesions, especially if present at onset<sup>c</sup>
  - d. Longitudinally extensive optic nerve lesion (e.g.,  $>1/2$  of the length of the pre-chiasmal optic nerve, T2 or T1/Gd)<sup>d</sup>
  - e. Periopic Gd enhancement during acute ON<sup>e</sup>
  - f. Normal supratentorial MRI in patients with acute ON, myelitis and/or brainstem encephalitis
  - g. Brain MRI abnormal but no lesion adjacent to a lateral ventricle that is ovoid/round or associated with an inferior temporal lobe lesion and no Dawson's finger-type or juxtacortical U fiber lesion (Matthews-Jurynczyk criteria)<sup>f</sup>
  - h. Large, confluent T2 brain lesions suggestive of ADEM*Fundoscopy*
  - i. Prominent papilledema/papillitis/optic disc swelling during acute ON*CSF*
  - j. Neutrophilic CSF pleocytosis<sup>g</sup> or CSF WCC  $> 50/\mu\text{l}$ <sup>h</sup>
  - k. No CSF-restricted OCB as detected by IEF at first or any follow-up examination<sup>i</sup> (applies to continental European patients only)*Histopathology*
  - l. Primary demyelination with intralesional complement and IgG deposits
  - m. Previous diagnosis of "pattern II MS"<sup>j</sup>*Clinical findings*
  - n. Simultaneous bilateral acute ON
  - o. Unusually high ON frequency or disease mainly characterized by recurrent ON
  - p. Particularly severe visual deficit/blindness in one or both eyes during or after acute ON
  - q. Particularly severe or frequent episodes of acute myelitis or brainstem encephalitis
  - r. Permanent sphincter and/or erectile disorder after myelitis
  - s. Patients diagnosed with "ADEM", "recurrent ADEM", "multiphasic ADEM" or "ADEM-ON"
  - t. Acute respiratory insufficiency, disturbance of consciousness, behavioral changes, or epileptic seizures (radiological signs of demyelination required)
  - u. Disease started within 4 days to ~4 weeks after vaccination
  - v. Otherwise unexplained intractable nausea and vomiting or intractable hiccups (compatible with area postrema syndrome)<sup>a</sup>
  - w. Co-existing teratoma or NMDAR encephalitis (low evidence)<sup>k</sup>*Treatment response*
  - x. Frequent flare-ups after IVMP, or steroid-dependent symptoms<sup>l</sup> (including CRION)
  - y. Clear increase in relapse rate following treatment with IFN-beta or natalizumab in patients diagnosed with MS (low evidence)

## International Panel on NMOSD

The International Panel on NMOSD recommends "testing with cell-based serum assays (microscopy or flow cytometry-based detection) whenever possible because they optimize autoantibody detection (mean sensitivity 76.7% in a pooled analysis; 0.1% false-positive rate in a MS clinic cohort)." They state that ELISA and indirect immunofluorescence assays have lower sensitivity and "strongly" recommend "interpretative caution if such assays are used and when low-titer positive ELISA results are detected in individuals who present with NMOSD clinical symptoms less commonly associated with AQP4-IgG (e.g., presentations other than recurrent optic neuritis, myelitis with LETM, or area postrema syndrome) or in situations where clinical evidence suggests a viable alternate diagnosis. Confirmatory testing is recommended, ideally using 1 or more different AQP4-IgG assay techniques. Cell-based assay has the best

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

current sensitivity and specificity and samples may need to be referred to a specialized laboratory.” The table below outlines the NMOSD diagnostic criteria for adult patients (Wingerchuk et al., 2015).

<b>Table 1</b>	<b>NMOSD diagnostic criteria for adult patients</b>
<b>Diagnostic criteria for NMOSD with AQP4-IgG</b>	
<ol style="list-style-type: none"><li>1. At least 1 core clinical characteristic</li><li>2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended)</li><li>3. Exclusion of alternative diagnoses<sup>a</sup></li></ol>	
<b>Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status</b>	
<ol style="list-style-type: none"><li>1. At least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:<ol style="list-style-type: none"><li>a. At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome</li><li>b. Dissemination in space (2 or more different core clinical characteristics)</li><li>c. Fulfillment of additional MRI requirements, as applicable</li></ol></li><li>2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable</li><li>3. Exclusion of alternative diagnoses<sup>a</sup></li></ol>	
<b>Core clinical characteristics</b>	
<ol style="list-style-type: none"><li>1. Optic neuritis</li><li>2. Acute myelitis</li><li>3. Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting</li><li>4. Acute brainstem syndrome</li><li>5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions (figure 3)</li><li>6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions (figure 3)</li></ol>	

---

## National Institute for Health and Care Excellence (NICE)

The 2022 NICE guidelines on MS in adults recommends diagnosing MS using “combination of history, examination, MRI and laboratory findings, and by following the 2017 revised McDonald criteria” and notes that this should include “looking for cerebrospinal fluid-specific oligoclonal bands if there is no clinical or radiological evidence of lesions developing at different times” (NICE, 2022).

---

## Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at [www.bcbsnc.com](http://www.bcbsnc.com). They are listed in the Category Search on the Medical Policy search page.

*Applicable codes:* 83520, 83916, 84182, 86051, 86052, 86053, 86362, 86363, 88341, 88342

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

## Scientific Background and Reference Sources

---

Benkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., Lalive, P. H., Mueller, C., Müller, S., Naegelin, Y., Oksenberg, J. R., Pot, C., Salmen, A., Willemse, E., Kockum, I., . . . Kuhle, J. (2022). Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *Lancet Neurol*, 21(3), 246-257. [https://doi.org/10.1016/s1474-4422\(22\)00009-6](https://doi.org/10.1016/s1474-4422(22)00009-6)

Brownlee, W. J., Hardy, T. A., Fazekas, F., & Miller, D. H. (2017). Diagnosis of multiple sclerosis: progress and challenges. *Lancet*, 389(10076), 1336-1346. [https://doi.org/10.1016/s0140-6736\(16\)30959-x](https://doi.org/10.1016/s0140-6736(16)30959-x)

Cantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., Henry, R. G., Cree, B. A. C., Kappos, L., Leppert, D., Hauser, S. L., Benkert, P., Oksenberg, J. R., & Kuhle, J. (2019). Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. *JAMA Neurol*, 76(11), 1359-1366. <https://doi.org/10.1001/jamaneurol.2019.2137>

Comabella, M., & Montalban, X. (2014). Body fluid biomarkers in multiple sclerosis. *Lancet Neurol*, 13(1), 113-126. [https://doi.org/10.1016/s1474-4422\(13\)70233-3](https://doi.org/10.1016/s1474-4422(13)70233-3)

Comabella, M., Sastre-Garriga, J., & Montalban, X. (2016). Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. *Curr Opin Neurol*, 29(3), 254-262. <https://doi.org/10.1097/wco.0000000000000336>

El Ayoubi, N. K., & Khoury, S. J. (2017). Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. *Neurotherapeutics*, 14(1), 135-147. <https://doi.org/10.1007/s13311-016-0486-7>

Eriksson, M., Andersen, O., & Runmarker, B. (2003). Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. *Mult Scler*, 9(3), 260-274. <https://doi.org/10.1191/1352458503ms914oa>

FDA. (2016). 510k. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf16/K161951.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161951.pdf)

Filippi, M., & Rocca, M. A. (2011). MR imaging of multiple sclerosis. *Radiology*, 259(3), 659-681. <https://doi.org/10.1148/radiol.11101362>

Fryer, J. P., Lennon, V. A., Pittock, S. J., Jenkins, S. M., Fallier-Becker, P., Clardy, S. L., Horta, E., Jedynek, E. A., Lucchinetti, C. F., Shuster, E. A., Weinshenker, B. G., Wingerchuk, D. M., & McKeon, A. (2014). AQP4 autoantibody assay performance in clinical laboratory service. *Neurol Neuroimmunol Neuroinflamm*, 1(1), e11. <https://doi.org/10.1212/nxi.0000000000000011>

Gil-Perotin, S., Castillo-Villalba, J., Cubas-Nuñez, L., Gasque, R., Hervas, D., Gomez-Mateu, J., Alcalá, C., Perez-Miralles, F., Gascon, F., Dominguez, J. A., & Casanova, B. (2019). Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. *Front Neurol*, 10, 1008. <https://doi.org/10.3389/fneur.2019.01008>

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

Glisson, C. C. (2022). Neuromyelitis optica spectrum disorders. Wolters Kluwer. <https://www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorders>

Goodin, D. S. (2014). The epidemiology of multiple sclerosis: insights to disease pathogenesis. *Handb Clin Neurol*, 122, 231-266. <https://doi.org/10.1016/b978-0-444-52001-2.00010-8>

Hyun, J. W., Kim, W., Huh, S. Y., Park, M. S., Ahn, S. W., Cho, J. Y., Kim, B. J., Lee, S. H., Kim, S. H., & Kim, H. J. (2018). Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. *Mult Scler*, 1352458518790702. <https://doi.org/10.1177/1352458518790702>

Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., Kleiter, I., Kümpfel, T., Levy, M., Palace, J., Ruprecht, K., Saiz, A., Trebst, C., Weinshenker, B. G., & Wildemann, B. (2018). MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. *Journal of Neuroinflammation*, 15, 134. <https://doi.org/10.1186/s12974-018-1144-2>

Jitprapaikulsan, J., Chen, J. J., Flanagan, E. P., Tobin, W. O., Fryer, J. P., Weinshenker, B. G., McKeon, A., Lennon, V. A., Leavitt, J. A., Tillema, J. M., Lucchinetti, C., Keegan, B. M., Kantarci, O., Khanna, C., Jenkins, S. M., Spears, G. M., Sagan, J., & Pittock, S. J. (2018). Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. *Ophthalmology*, 125(10), 1628-1637. <https://doi.org/10.1016/j.ophtha.2018.03.041>

Koch, M., Kingwell, E., Rieckmann, P., & Tremlett, H. (2009). The natural history of primary progressive multiple sclerosis. *Neurology*, 73(23), 1996-2002. <https://doi.org/10.1212/WNL.0b013e3181c5b47f>

Lim, C. K., Bilgin, A., Lovejoy, D. B., Tan, V., Bustamante, S., Taylor, B. V., Bessede, A., Brew, B. J., & Guillemin, G. J. (2017). Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. *Sci Rep*, 7, 41473. <https://doi.org/10.1038/srep41473>

Lotze, T. E. (2019/2022). Differential diagnosis of acute central nervous system demyelination in children. Wolters Kluwer. <https://www.uptodate.com/contents/differential-diagnosis-of-acute-central-nervous-system-demyelination-in-children>

Lublin, F. D., Coetzee, T., Cohen, J. A., Marrie, R. A., Thompson, A. J., & International Advisory Committee on Clinical Trials in, M. S. (2020). The 2013 clinical course descriptors for multiple sclerosis: A clarification. *Neurology*, 94(24), 1088-1092. <https://doi.org/10.1212/WNL.0000000000009636>

Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology*, 46(4), 907-911. <http://dx.doi.org/>

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sorensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Jr., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., . . . Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, 83(3), 278-286. <https://doi.org/10.1212/wnl.0000000000000560>

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

Luzzio, C. (2019). Multiple Sclerosis Guidelines.

<https://emedicine.medscape.com/article/1146199-guidelines>

Martin, S.J., McGlasson, S., Hunt, D., & Overell, J. (2019). Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.

*Journal of Neurology, Neurosurgery & Psychiatry*, 90(9), 1059.

<https://doi.org/10.1136/jnnp-2018-319190>

NICE. (2022). Multiple sclerosis in adults: management.

<https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#diagnosing-multiple-sclerosis>

Offenbacher, H., Fazekas, F., Schmidt, R., Freidl, W., Flooh, E., Payer, F., & Lechner, H. (1993). Assessment of MRI criteria for a diagnosis of MS. *Neurology*, 43(5), 905-909.

<http://dx.doi.org/>

Olek, M., Howard, Jonathan. (2022a). Clinical course and classification of multiple sclerosis - UpToDate. In J. Dashe (Ed.), UpToDate. <https://www.uptodate.com/contents/clinical-presentation-course-and-prognosis-of-multiple-sclerosis-in-adults>

Olek, M., Howard, Jonathan. (2022b). Evaluation and diagnosis of multiple sclerosis in adults. In J. Dashe (Ed.), UpToDate. <https://www.uptodate.com/contents/evaluation-and-diagnosis-of-multiple-sclerosis-in-adults>

Raphael, I., Webb, J., Stuve, O., Haskins, W. E., & Forsthuber, T. G. (2015). Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. *Expert Rev Clin Immunol*, 11(1), 69-91.

<https://doi.org/10.1586/1744666x.2015.991315>

Rovira, A., Swanton, J., Tintore, M., Huerga, E., Barkhof, F., Filippi, M., Frederiksen, J. L., Langkilde, A., Miszkiel, K., Polman, C., Rovaris, M., Sastre-Garriga, J., Miller, D., & Montalban, X. (2009). A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. *Arch Neurol*, 66(5), 587-592. <https://doi.org/10.1001/archneurol.2009.49>

Sapko, K., Jamroz-Wisniewska, A., Marciniak, M., Kulczynski, M., Szczepanska-Szerej, A., & Rejdak, K. (2020). Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. *Neurol Neurochir Pol*, 54(3), 252-258. <https://doi.org/10.5603/PJNNS.a2020.0037>

Schaffler, N., Kopke, S., Winkler, L., Schippling, S., Inglese, M., Fischer, K., & Heesen, C. (2011). Accuracy of diagnostic tests in multiple sclerosis--a systematic review. *Acta Neurol Scand*, 124(3), 151-164. <https://doi.org/10.1111/j.1600-0404.2010.01454.x>

Simonsen, C. S., Flemmen, H., Lauritzen, T., Berg-Hansen, P., Moen, S. M., & Celius, E. G. (2020). The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. *Mult Scler J Exp Transl Clin*, 6(1), 2055217319901291. <https://doi.org/10.1177/2055217319901291>

Sotirchos, E. S., Filippatou, A., Fitzgerald, K. C., Salama, S., Pardo, S., Wang, J., Ogbuokiri, E., Cowley, N. J., Pellegrini, N., Murphy, O. C., Mealy, M. A., Prince, J. L., Levy, M., Calabresi, P. A., & Saidha, S. (2019). Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. *Mult Scler*, 1352458519864928. <https://doi.org/10.1177/1352458519864928>

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015). Body fluid biomarkers for multiple sclerosis--the long road to clinical application. *Nat Rev Neurol*, 11(10), 585-596. <https://doi.org/10.1038/nrneurol.2015.173>

Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*, 17(2), 162-173. [https://doi.org/10.1016/s1474-4422\(17\)30470-2](https://doi.org/10.1016/s1474-4422(17)30470-2)

Wallin, M. T., Culpepper, W. J., Campbell, J. D., Nelson, L. M., Langer-Gould, A., Marrie, R. A., Cutter, G. R., Kaye, W. E., Wagner, L., Tremlett, H., Buka, S. L., Dilokthornsakul, P., Topol, B., Chen, L. H., & LaRocca, N. G. (2019). The prevalence of MS in the United States: A population-based estimate using health claims data. *Neurology*, 92(10), e1029-e1040. <https://doi.org/10.1212/wnl.0000000000007035>

Weinshenker, B. G. (1994). Natural history of multiple sclerosis. *Ann Neurol*, 36 Suppl, S6-11. <http://dx.doi.org/>

Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J. H., Tenenbaum, S., Traboulsee, A. L., Waters, P., Wellik, K. E., & Weinshenker, B. G. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*, 85(2), 177-189. <https://doi.org/10.1212/wnl.0000000000001729>

## Policy Implementation/Update Information

---

- 1/1/19 New policy developed. BCBSNC will provide coverage for serum biomarker testing for multiple sclerosis and related neurologic diseases when it is determined to be medically necessary because the medical criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (sk)
- 10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed (gm)
- 11/26/19 Specialty Matched Consultant Advisory Panel review 10/16/2019. (sk)
- 12/10/19 Reviewed by Avalon 3rd Quarter CAB. No change in overall intent of policy. (sk)
- 11/10/20 Specialty Matched Consultant Advisory Panel review 10/21/2020. Reviewed by Avalon 3rd Quarter 2020 CAB. Description section updated. Regulatory section updated. Coverage criteria updated with addition of criteria for cerebrospinal fluid (CSF) and serum oligoclonal band analysis for multiple sclerosis. Policy Guidelines updated. Code 83916 added to Billing/Coding section. References updated. (sk)
- 11/16/21 Specialty Matched Consultant Advisory Panel review 10/20/2021. Reviewed by Avalon 3rd Quarter 2021 CAB. Description section updated. Regulatory section updated. Policy Guidelines updated. References updated. (sk)
- 12/30/21 Added codes 86051, 86052, 86053, 86362, and 86363 to Billing/Coding section. (sk)
- 12/13/22 Reviewed by Avalon 3rd Quarter 2022 CAB. Description section updated. Regulatory section updated. Table of Terminology added. Policy Guidelines updated. Codes 86255 and 86256 removed from Billing/Coding section. References updated. (sk)

# Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases AHS – G2123

---

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.